BRIEF-Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer
June 26, 2017 at 08:42 AM EDT
* Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer
